ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1026

Autoinflammatory Diseases, Particularly SAVI and Candle, Are Driven By Chronically Active Type I Interferons

Bernadette Marrero1, Katherine R. Calvo2, Yin Liu3, Angelique Biancotto4, Yan Huang1 and Raphaela Goldbach-Mansky1, 1Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, 2Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, 3Scientific Review Branch, NIAMS/NIH, Bethesda, MD, 4Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoinflammation, innate immunity, interferons and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: STING Associated Vasculopathy with onset in Infancy (SAVI)is caused by gain-of-function mutations in TMEM173/STING and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) by loss-of-function mutations in proteasome subunits. Both are IFN-mediated disease but the origin of the IFN production has not been systematically evaluated in patients. The purpose of our study was to determine the cellular origin of IFNs, from SAVI and CANDLE patients (PTs) compared to healthy controls (HC).

Methods: We evaluated sorted PBMCs (n=5 HC, PTs) and lesional skin biopsies (n=2-3 HC, PTs) for detection of IFN production by qRT-PCR.

Results: In both diseases, pan-interferon (IFN)-α serum levels are 8 and 25-fold increased, respectively. PTs had a mean of 12-fold increase in IFN-response-gene (IRG) signatures compared to HC. SAVI pts. constitutively expressed elevated IFN-transcript levels and qPCR results showed a 450-fold and 280-fold increase in IFNB1 [IQR 0.5-61, 60.6], and 3.5-fold and 4.4-fold increase in IFNA7 [IQR 0-2.93, 2.93] transcription in monocytes (n=5) and dendritic cells (n=3) respectively, compared to CANDLE and HC. During disease flares but not at rest, CANDLE monocytes increased IFNB1 production 4.6 and 184-fold and IFNA72.5 to 110-fold (n=2). In contrast to CANDLE and HC monocytes, SAVI monocytes cannot be differentiated into macrophage and 82%±14 SD died in culture within 24-hours. SAVI monocytes expressed 24-fold increase of actively cleaved caspase-1 in the supernatant from the immunoblot analysis compared to HC and did not show active form of caspase-3. ELISA demonstrated low expression of IL-1b β the supernatant and immunofluorescence showed elevated intracellular staining of gasdermin-D and NLRP3, suggesting cell death occurs through pyroptosis.

Conclusion: The cellular sources of IFN production vary in CANDLE and SAVI; Type I IFN transcription in SAVI patients occurs mainly in monocytes and in dendritic cells, in contrast, in CANDLE patients, Type I IFNs are only expressed in monocytes prior to JAK inhibitor treatment during a disease flare (Tx). However interferon-response genes are expressed in all cell types. Constitutively active STING from SAVI monocytes undergo rapid cell death in culture,which may indicate rapid cell turnover in the blood. Studies evaluating the mechanism that leads to monocyte death is ongoing. Understanding the signaling pathways in autoinflammatory diseases assocaited with high IFN signatures is important in our ability to identify and interpret biomarkers that will aid in the diagnosis and the design of targeted treatments.


Disclosure: B. Marrero, None; K. R. Calvo, None; Y. Liu, None; A. Biancotto, None; Y. Huang, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Marrero B, R. Calvo K, Liu Y, Biancotto A, Huang Y, Goldbach-Mansky R. Autoinflammatory Diseases, Particularly SAVI and Candle, Are Driven By Chronically Active Type I Interferons [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/autoinflammatory-diseases-particularly-savi-and-candle-are-driven-by-chronically-active-type-i-interferons/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoinflammatory-diseases-particularly-savi-and-candle-are-driven-by-chronically-active-type-i-interferons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology